Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 22, 2009

ArmaGen Chooses PacificGMP to Manufacture Fusion Protein for Phase I Trial in Stroke and Parkinson’s

  • ArmaGen Technologies has selected PacificGMP to produce its treatment for stroke or Parkinson's disease for a Phase I trial. PacificGMP will use a perfusion process to produce the antibody fusion protein, AGT-190, under cGMP standards. Additionally, PacificGMP will perform cGMP cell bank development.

    The AGT-190 fusion protein is a bi-functional molecule: It attaches to a receptor on the human blood-brain barrier (BBB) to effect transport into the brain from blood, and it attaches to a specific neurotrophin receptor on brain cells to protect the cells from cellular damage. AGT-190 comprises a human neurotrophin that causes neuroprotection in the brain. Since the neurotrophin cannot cross the BBB, it is thus fused to another protein that undergoes receptor-mediated transport across the human BBB. The second protein acts as a molecular Trojan horse to ferry the therapeutic neurotrophin across the BBB.

    PacificGMP points out that using the perfused method of manufacturing provides significant economic and timeline advantages. Perfusion is a production technology whereby culture media containing the drug product is continually harvested while the bioreactor is replenished with fresh media containing essential nutrients. The result is a dense cell culture able to produce necessary yields using a smaller bioreactor size compared to a traditional batch or fed-batch process.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »